Dr Tina Caroline Flatau

Dr. Tina Caroline Flatau has established a distinguished career in the biopharmaceutical industry, spanning more than two decades. She holds a PhD in pharmaceutical sciences and has played pivotal roles across various sectors of the industry, from research and development to operational management in multinational corporations and startups in the USA, EU, and UK. Dr. Flatau was a Principal in PwC’s Pharmaceutical Industry Group before becoming the Vice President at Prosensa Therapeutics, where she managed the pipeline of antisense therapies and oversaw the business aspects of the company’s successful IPO on NASDAQ in 2013, which was later acquired by BioMarin. She has authored patents in T-cell modulation for oncology therapies, which are now in clinical Phase II trials in the UK. Additionally, Dr. Flatau has founded biotech companies such as MedAnnex Ltd and aTen Therapeutics Ltd, focusing on developing monoclonal antibodies for annexin-A1 and angiotensin II modulation, with MedAnnex securing an £11 million funding round in 2019. Beyond her corporate roles, she is actively involved in the healthcare community as a board member and former Chair of the rare disease charity Action Duchenne, and as a member of the NHS Health Research Authority Research Ethics Committee.